New COX-2/5-LOX inhibitors: Apoptosis-inducing agents potentially useful in prostate cancer chemotherapy

Journal of Medicinal Chemistry

Volumn 47, Issue 25, 2004, Pages 6195-6206

  Pommery, Nicole ^a   Taverne, Thierry ^a   Telliez, Aurélie ^a   Goossens, Laurence ^a   Charlier, Caroline ^b   Pommery, Jean ^a   Goossens, Jean François ^a   Houssin, Raymond ^a   Durant, François ^b   Hénichart, Jean Pierre ^a  

^a Faculté des Sciences Pharmaceutiques et Biologiques Université de Lille   (France)

^b UNIVERSITY OF NAMUR   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; LIPOXYGENASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POLYUNSATURATED FATTY ACID; PYRAZOLE DERIVATIVE; ROFECOXIB; ZILEUTON;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARACHIDONIC ACID METABOLISM; ARTICLE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; DERIVATIZATION; ENZYME METABOLISM; FATTY ACID METABOLISM; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOLECULAR MODEL; PHARMACOPHORE; PROSTATE CANCER; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARACHIDONATE 5-LIPOXYGENASE; CELL LINE, TUMOR; CELL PROLIFERATION; CHO CELLS; CRICETINAE; CYCLOOXYGENASE 2; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; ISOENZYMES; MALE; MEMBRANE PROTEINS; MODELS, MOLECULAR; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTATIC NEOPLASMS; PYRAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 9744265658     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0407761     Document Type: Article

References (43)

1. Cuendet, M.; Pezzuto, J. M. The role of cyclooxygenase and lipoxygenase in cancer chemoprevention. Drug Metabol. Drug Interact. 2000, 17, 109-157.
2. Nie, D.; Honn, K. V. Cyclooxygenase, lipoxygenase and tumor angiogenesis. Cell Mol. Life Sci. 2002, 59, 799-807.
3. Gasparini, G.; Longo, R.; Sarmiento, R.; Morabito, A. Inhibitors of cyclo-oxygenase 2: A new class of anticancer agents? Lancet Oncol. 2003, 4, 605-615.
4. Haller, D. G. COX-2 inhibitors in oncology. Semin. Oncol. 2003, 30, 2-8.
5. Nie, D.; Che, M.; Grignon, D.; Tang, K.; Honn, K. V. Role of eicosanoids in prostate cancer progression. Cancer Metastasis Rev. 2001, 20, 195-206.
6. Gupta, S.; Srivastava, M.; Ahmad, N.; Bostwick, D. G.; Mukhtar, H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000, 42, 73-78.
7. Madaan, S.; Abel, P. D.; Chaudhary, K. S.; Heyritt, R.; Stott, M. A.; Stamp, G. W.; Lalani, E. N. Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: Implications for prevention and treatment. BJU Int. 2000, 86, 736-741.
8. Hussain, T.; Gupta, S.; Mukhtar, H. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett. 2003, 191, 125-135.
9. Sabichi, A. L.; Lippman, S. M. COX-2 inhibitors and other NSAIDs in bladder and prostate cancer. Prog. Exp. Tumor Res. 2003, 37, 163-178.
10. Attiga, F. A.; Fernandez, P. M.; Weeraratna, A. T.; Manyak, M. J.; Patierno, S. R. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res. 2000, 60, 4629-4637.
11. Shureiqi, I.; Lippman, S. M. Lipoxygenase modulation to reverse carcinogenesis. Cancer Res. 2001, 61, 6307-6312.
12. Pidgeon, G. P.; Kandouz, M.; Meram, A.; Honn, K. V. Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells. Cancer Res. 2002, 62, 2721-2727.
13. Hsi, L. C.; Wilson, L. C.; Eling, T. E. Opposing effects of 15-lipoxygenase-1 and -2 metabolites on MAPK signalling in prostate. Alteration in peroxisome proliferators-activated receptor gamma. J. Biol. Chem. 2002, 277, 40549-40556.
14. Shappell, S. B.; Gupta, R. A.; Manning, S.; Whitehead, R.; Boeglin, W. E.; Schneider, C.; Case, T.; Price, J.; Jack, G. S.; Wheeler, T. M.; Matusik, R. J.; Brash, A. R.; DuBois, R. N. (15S)-hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor γ and inhibits proliferation in PC 3 prostate carcinoma cells. Cancer Res. 2001, 61, 497-503.
15. Kelavkar, U. P.; Nixon, J. B.; Cohen, C.; Dillehay, D.; Eling, T. E.; Badr, K. F. Overexpression of 15-lipoxygenase-1 in PC 3 human prostate cancer cells increases tumorigenesis. Carcinogenesis 2001, 22, 1765-1773.
16. Anderson, K. M.; Seed, T.; Vos, M.; Mulshine, J.; Meng, J.; Alrefai, W.; Ou, D.; Harris, J. E. 5-lipoxygenase inhibitors reduce PC 3 cell proliferation and initiate non-necrotic cell death. Prostate 1998, 37, 161-173.
17. Liu, X. H.; Kirschenbaum, A.; Yao, S.; Lee, R.; Holland, J. F.; Levine, A. C. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J. Urol. 2000, 164, 820-825.
18. Song, X.; Lin, H. P.; Johnson, A.; Tseng, P. H.; Yang, Y. T.; Kulp, S. K.; Chen, C. S. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J. Natl. Cancer Inst. 2002, 94, 585-591.
19. Zhu, J.; Song, X.; Lin, H. P.; Young, D. C.; Yan, S.; Marquez, V. E.; Chen, C. S. Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. J. Natl. Cancer Inst. 2002, 94, 1745-1757.
20. Marx, J. Cancer research. Anti-inflammatories inhibit cancer growth-But how? Science 2001, 291, 581-582.
21. Srinath, P.; Rao, P. N.; Knaus, E. E.; Suresh, M. R. Effect of cyclooxygenase-2 (COX-2) inhibitors on prostate cancer cell proliferation. Anticancer Res. 2003, 23, 3923-3928.
22. Gugliucci, A.; Ranzato, L.; Scorrano, L.; Colonna, R.; Petronilli, V.; Cusan, C.; Prato, M.; Mancini, M.; Pagano, F.; Bernardi, P. Mitochondria are direct targets of the lipoxygenase inhibitor MK886. A strategy for cell killing by combined treatment with MK886 and cyclooxygenase inhibitors. J. Biol. Chem. 2002, 277, 31789-31795.
23. Barbey, S.; Goossens, L.; Taverne, T.; Cornet, J.; Choesmel, V.; Rouaud, C.; Gimeno, G.; Yannic-Arnoult, S.; Michaux, C.; Charlier, C.; Houssin, R.; Hénichart, J.-P. Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2/5-lipoxygenase inhibitor. Bioorg. Med. Chem. Lett. 2002, 12, 779-782.
24. Crawley, G. C.; Dowell, R. I.; Edwards, P. N.; Foster, S.; MacMillan, R. M.; Walker, E. R. H.; Waterson, P. Methoxytetrahydropyrans. A new series of selective and orally potent 5-lipoxygenase inhibitors. J. Med. Chem. 1992, 35, 2600-2609.
25. 2-symmetric (S,S)-1,4-dibenzyl-DTPA and 1,4-meso-dibenzyl-DTPA via chiral diamines. Tetrahedron 1996, 52, 14507-14514.
26. Charlier, C.; Michaux, C. Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. Eur. J. Med. Chem. 2003, 38, 645-659.
27. Garavito, R. M.; Malkowski, M. G.; DeWitt, D. L. The structures of prostaglandin endoperoxide H synthases-1 and -2. Prostaglandins Other Lipid Mediat. 2002, 68-69, 129-152.
28. Kurumbail, R. G.; Stevens, A. M.; Gierse, J. K.; McDonald, J. J.; Stegeman, R. A.; Pak, J. Y.; Gildehaus, D.; Miyashiro, J. M.; Penning, T. D.; Seibert, K.; Isakson, P. C.; Stallings, W. C. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996, 384, 644-648.
29. Rowlinson, S. W.; Kiefer, J. R.; Prusakiewicz, J. J.; Pawlitz, J. L.; Kozak, K. R.; Kalgutkar, A. S.; Stallings, W. C.; Kurumbail, R. G.; Marnett, L. J. A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385. J. Biol. Chem. 2003, 278, 45763-45769.
30. Goodford, P. J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 1985, 28, 849-857.
31. Kazanov, D.; Dvory-Sobol, H.; Pick, M.; Liberman, E.; Strier, L.; Choen-Noyman, E.; Deutsch, V.; Kunik, T.; Arber, N. Celecoxib but not rofecoxib inhibits the growth of transformed cells in vitro. Clin. Cancer Res. 2004, 10, 267-271.
32. Grosch, S.; Tegeder, L; Niederberger, E.; Brautigam, L.; Geisslinger, G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J. 2001, 15, 2742-2744.
33. Kundu, N.; Smyth, M. J.; Samsel, L.; Fulton, A. M. Cyclooxygenase inhibitors block cell growth, increase ceramide and inhibit cell cycle. Breast Cancer Res. Treat. 2002, 76, 57-64.
34. Seelan, R. S.; Qian, C.; Yokomizo, A.; Bostwick, D. G.; Smith, D. I.; Liu, W. Human acid ceramidase is overexpressed but not mutated in prostate cancer. Genes Chromosomes Cancer 2000, 29, 137-146.
35. Mimeault, M.; Pommery, N.; Wattez, N.; Bailly, C.; Hénichart, J.-P. Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: Implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate 2003, 56, 1-12.
36. Zha, S.; Gage, W. R.; Sauvageot, J.; Saria, E. A.; Putzi, M. J.; Ewing, C. M.; Faith, D. A.; Nelson, W. G.; De Marzo, A. M.; Isaacs, W. B. Cyclooxygenase-2 is upregulated in proliferative inflammatory atrophy of the prostate but not in prostate carcinoma. Cancer Res. 2001, 61, 8617-8623.
37. Weis, C. D. Ger. Offen. 2,827,062, 1979; Chem. Abstr. 1979, 90, 151814e.
38. Brecker, L.; Pogorevc, H.; Griengl, H.; Steiner, W.; Kappe, T.; Ribbons, D. W. Synthesis of 2,4-diketo acids and their aqueous solution structures. New J. Chem. 1999, 23, 437-446.
39. InsightII; version 2000; Accelrys Inc.: San Diego, CA.
40. Jones, G.; Willett, P.; Glen, R. C. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J. Mol. Biol. 1995, 245, 43-53.
41. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
42. Discover, Force field Simulations, User guide, Part 1; Biosym/MSI: San Diego, CA, 1996.
43. Homology, User guide; Biosym/MSI: San Diego, CA, 1993.